Therapeutic approach to hyponatremia. 2002

Dae-Suk Han, and Byoung-Soo Cho
Department of Internal Medicine, College of Medicine, Yonsei University, Korea. dshan@yumc.yonsei.ac.kr

Hyponatremia is a relatively common disorder occurring in up to 6% of hospitalized patients and can occur through any mechanism that produces a relative excess of body water to body sodium. Although most hyponatremia patients are asymptomatic, severe symptomatic hyponatremia is a medical emergency that may lead to cerebral edema, tentorial herniation and death. More aggressive therapy is indicated in these patients. However, in some patients, the treatment itself may result in central nervous system demyelination that may be associated with permanent neurologic sequelae. The therapeutic strategy that should guide optimal treatment of hyponatremia requires attention to the following four factors: the patient's volume status, the presence or absence of symptoms, duration of hypo-osmolality, and the presence or absence of risk factors for the development of neurologic complication. An initial categorization according to the clinical ECF volume status of the patient will allow a determination of the appropriate initial therapy in the majority of cases. The importance of duration of hyponatremia and the presence or absence of symptoms relates to how well the brain has adapted to the hyponatremia. The severity of hyponatremia is also an important consideration because osmotic demyelination is rarely seen in patients with the initial serum sodium greater than 120 mEq/l. Clinical surveys have identified subgroups of patients at greatest risk for developing neurologic complication of hyponatremia. Optimal therapy of these patients must consider balancing the risks of hyponatremia against the risks of correction for each patient individually. Although individual variability in response to treatment is considerable, consensus guidelines for treating hyponatremic patients allow a rational and safe therapeutic approach to minimize the neurologic complications.

UI MeSH Term Description Entries
D007010 Hyponatremia Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed) Hyponatremias
D001834 Body Water Fluids composed mainly of water found within the body. Water, Body
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005110 Extracellular Space Interstitial space between cells, occupied by INTERSTITIAL FLUID as well as amorphous and fibrous substances. For organisms with a CELL WALL, the extracellular space includes everything outside of the CELL MEMBRANE including the PERIPLASM and the cell wall. Intercellular Space,Extracellular Spaces,Intercellular Spaces,Space, Extracellular,Space, Intercellular,Spaces, Extracellular,Spaces, Intercellular
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012964 Sodium A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23. Sodium Ion Level,Sodium-23,Ion Level, Sodium,Level, Sodium Ion,Sodium 23
D065092 Antidiuretic Hormone Receptor Antagonists Endogenous compounds and drugs that inhibit or block the activity of ANTIDUIRETIC HORMONE RECEPTORS. Antidiuretic Hormone Antagonist,Antidiuretic Hormone Receptor Antagonist,Vasopressin Antagonist,Vasopressin Receptor Antagonist,Antidiuretic Hormone Antagonists,Vasopressin Antagonists,Vasopressin Receptor Antagonists,Antagonist, Antidiuretic Hormone,Antagonist, Vasopressin,Antagonist, Vasopressin Receptor,Antagonists, Antidiuretic Hormone,Antagonists, Vasopressin,Antagonists, Vasopressin Receptor,Hormone Antagonist, Antidiuretic,Hormone Antagonists, Antidiuretic,Receptor Antagonist, Vasopressin,Receptor Antagonists, Vasopressin

Related Publications

Dae-Suk Han, and Byoung-Soo Cho
January 2017, Case reports in nephrology,
Dae-Suk Han, and Byoung-Soo Cho
November 1979, Israel journal of medical sciences,
Dae-Suk Han, and Byoung-Soo Cho
August 2011, Deutsche medizinische Wochenschrift (1946),
Dae-Suk Han, and Byoung-Soo Cho
July 1980, Archives of internal medicine,
Dae-Suk Han, and Byoung-Soo Cho
April 2019, Clinical liver disease,
Dae-Suk Han, and Byoung-Soo Cho
February 2023, Cureus,
Dae-Suk Han, and Byoung-Soo Cho
November 2010, Revue medicale suisse,
Dae-Suk Han, and Byoung-Soo Cho
November 1998, Internal medicine (Tokyo, Japan),
Dae-Suk Han, and Byoung-Soo Cho
January 2011, Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia,
Dae-Suk Han, and Byoung-Soo Cho
November 2014, Indian journal of endocrinology and metabolism,
Copied contents to your clipboard!